CD40LG and cancer: Nevertheless, the use of serum sCD40L as a single biomarker for PDAC may be limited because serum sCD40L can be elevated in other cancers[20-22] and certain benign disorders including cardiovascular diseases or immuno-inflammatory diseases[9,10].